---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331512"
form_type: "8-K"
ticker: "ODTX"
cik: "0001882782"
company_name: "Odyssey Therapeutics, Inc."
filed_at: "2026-08-04T11:00:16+00:00"
generated_at: "2026-08-04T11:06:36.578725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week

## Summary
- Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.
- Cash, cash equivalents and marketable securities $433.1M as of June 30, 2026; expected to fund operations into 2H 2028.
- R&D expenses $36.2M (up from $30.2M); G&A $10.5M (down from $13.2M).
- OD-001 Phase 2a data accepted for oral presentation at UEG Week in October; Phase 2b monotherapy and Phase 2a combo with vedolizumab expected to initiate in 2H 2026.
- OD-002 (SLC15A4 inhibitor) CTA filing expected in 2H 2026; Phase 1/2a trial initiation in 1H 2027.

## SEC filing metadata
- accession: 0001193125-26-331512
- form_type: 8-K
- ticker: ODTX
- cik: 0001882782
- company_name: Odyssey Therapeutics, Inc.
- filed_at: 2026-08-04T11:00:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/0001193125-26-331512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331512
- JSON: https://secwatch.observer/filing/0001193125-26-331512.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.